Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients
Status:
Completed
Trial end date:
2020-09-03
Target enrollment:
Participant gender:
Summary
The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in
combination with febuxostat or allopurinol when administered to gout patients.